Skip to content
NeuroView Technology
News & Publications
Research2 min read

NeuroView co-founder Dr. Ruben Kuzniecky co-authors review on the third wave of EEG technology in JCNP

A review supplement explores the promise of ultralong EEG recordings and the next frontier in neurological monitoring.

By NeuroView Research / Scientific Affairs

Publication overview

NeuroView co-founder R. Kuzniecky and F. Lado published a review supplement in the Journal of Clinical Neurophysiology titled "The Third Wave of EEG Technology: Exploring the Promise of Ultralong EEG Recordings."

The three waves of EEG

The authors describe three distinct eras of EEG technology, each expanding what the signal can capture and for how long.

  • First wave: clinical EEG for acute seizure diagnosis.
  • Second wave: ambulatory and video EEG for days-long outpatient monitoring.
  • Third wave: continuous ultralong EEG for chronic disease management and drug-response tracking.

Clinical implications

The review outlines the ability of ultralong EEG to capture rare seizure events, track therapy response over time, and generate longitudinal biomarker data for CNS drug trials.

Frequently asked questions

What is the third wave of EEG?

Continuous ultralong EEG systems capable of weeks and months of uninterrupted recording outside the hospital, used for chronic disease management.

Why does ultralong EEG matter for drug trials?

It generates longitudinal biomarker data and can track therapy response over time, which supports objective CNS trial endpoints.

Citation

Lado F, Kuzniecky R. The Third Wave of EEG Technology: Exploring the Promise of Ultralong EEG Recordings. J Clin Neurophysiol. 2024;41(3):193.

More from NeuroView